Parametrica Management Ltd acquired a new position in Integra LifeSciences Holdings Corp. (NASDAQ:IART) during the second quarter, Holdings Channel reports. The fund acquired 4,079 shares of the company’s stock, valued at approximately $325,000.

Other large investors have also recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Integra LifeSciences Holdings Corp. during the fourth quarter worth approximately $37,581,000. Loomis Sayles & Co. L P boosted its stake in shares of Integra LifeSciences Holdings Corp. by 39.0% in the first quarter. Loomis Sayles & Co. L P now owns 347,723 shares of the company’s stock worth $23,423,000 after buying an additional 97,494 shares during the last quarter. AXA purchased a new stake in shares of Integra LifeSciences Holdings Corp. during the first quarter worth approximately $3,782,000. Sector Gamma AS boosted its stake in shares of Integra LifeSciences Holdings Corp. by 21.8% in the first quarter. Sector Gamma AS now owns 301,457 shares of the company’s stock worth $20,306,000 after buying an additional 54,024 shares during the last quarter. Finally, Insight Capital Research & Management Inc. purchased a new stake in shares of Integra LifeSciences Holdings Corp. during the first quarter worth approximately $2,729,000. 88.47% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 0.13% on Friday, hitting $86.13. The stock had a trading volume of 335,482 shares. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of 355.91 and a beta of 0.52. The stock’s 50 day moving average is $84.88 and its 200 day moving average is $74.88. Integra LifeSciences Holdings Corp. has a one year low of $54.75 and a one year high of $88.86.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.03. Integra LifeSciences Holdings Corp. had a return on equity of 15.41% and a net margin of 0.79%. The business earned $249.30 million during the quarter, compared to analysts’ expectations of $243.17 million. During the same quarter in the prior year, the business earned $0.79 earnings per share. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Analysts anticipate that Integra LifeSciences Holdings Corp. will post $3.48 earnings per share for the current year.

IART has been the topic of a number of analyst reports. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $94.00 price objective (up previously from $86.00) on shares of Integra LifeSciences Holdings Corp. in a research note on Sunday, August 21st. Zacks Investment Research cut shares of Integra LifeSciences Holdings Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. JPMorgan Chase & Co. assumed coverage on shares of Integra LifeSciences Holdings Corp. in a research note on Wednesday, July 13th. They issued an “overweight” rating on the stock. Barclays PLC lifted their price target on shares of Integra LifeSciences Holdings Corp. from $74.00 to $77.00 and gave the company an “equal weight” rating in a research note on Thursday, June 2nd. Finally, Jefferies Group lifted their price target on shares of Integra LifeSciences Holdings Corp. from $81.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $82.88.

In other Integra LifeSciences Holdings Corp. news, Director Raymond G. Murphy sold 2,610 shares of the stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $84.83, for a total value of $221,406.30. Following the completion of the transaction, the director now owns 33,057 shares in the company, valued at $2,804,225.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Richard D. Gorelick sold 4,000 shares of the stock in a transaction on Monday, August 1st. The stock was sold at an average price of $84.60, for a total value of $338,400.00. Following the completion of the transaction, the vice president now owns 9,702 shares of the company’s stock, valued at approximately $820,789.20. The disclosure for this sale can be found here. Insiders own 22.00% of the company’s stock.

Integra LifeSciences Holdings Corp. Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

5 Day Chart for NASDAQ:IART

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corp. (NASDAQ:IART).

Receive News & Ratings for Integra LifeSciences Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.